RESUMEN
PURPOSE: Scaglietti introduced a method of steroid injection for the management of unicameral bone cysts in 1974. Subsequently the intralesional infiltration of corticosteriods has also been recommended as a primary therapy for localized Langerhanscell histiocytosis (LCH). We report our experience with the administration of methylprednisolone acetate in children and young adults localized LCH. MATERIAL AND METHODS: [corrected] Nine patients with localized LCH, aged 2 3/12 to 29 years, were treated with a single--in only one case two--intralesional injection of methylprednisolone acetate as a crystalline suspension. The dose was between 40 and 150 mg depending on the size of the radiolucent defect. We treated 4 lesions in the skull, 3 in the femur, 1 in the distal humerus and 1 in the mandibula. In each case the diagnosis was established by biopsy. Follow-up ranged from 2 to 8 8/12 years (4 years 4 months on average). RESULTS: 7 out of 9 patients with localized LCH had excellent results with complete healing of the lesion. In 2 patients there was no response to the initial injection therapy and dissemination of the disease occurred. In 4 patients with an additional soft tissue tumor, after injection therapy of the bone lesion, the soft tissue tumor resolved without further treatment. CONCLUSION: Intralesional infiltration of methylprednisolone acetate as a primary therapy for localized Langerhans cell histiocytosis leads to rapid relief of pain, restoration of bone morphology and reduction of associated soft tissue tumors. Performed with appropriate skill under sterile condition with the reported high percentage of effectiveness and low recurrence rate, this low invasive method is the treatment of choice, resulting in a lower morbidity and lower costs.
Asunto(s)
Antiinflamatorios/administración & dosificación , Enfermedades Óseas/tratamiento farmacológico , Histiocitosis de Células de Langerhans/tratamiento farmacológico , Metilprednisolona/análogos & derivados , Adolescente , Adulto , Antiinflamatorios/efectos adversos , Enfermedades Óseas/diagnóstico , Huesos/efectos de los fármacos , Huesos/patología , Niño , Preescolar , Diagnóstico por Imagen , Femenino , Histiocitosis de Células de Langerhans/diagnóstico , Humanos , Inyecciones Intralesiones , Masculino , Metilprednisolona/administración & dosificación , Metilprednisolona/efectos adversos , Acetato de MetilprednisolonaRESUMEN
The consequences of involuntary smoking are well documented. We conducted a survey among all employees of the University Hospital, Zurich, to assess their smoking habits and feelings about restrictions or a ban on smoking. In March 1995, a questionnaire was mailed to all 5230 hospital employees, 2620 (50.1%) completed forms were sent back. 76% of all staff are confronted with cigarette smoke during their worktime. 83% of these employees are distressed by tobacco smoke, and 43% feel that involuntary smoking affects their health. 19% of all employees are smokers. 19% of these are distressed by smokers at work themselves, whereas 13% feel that they are discriminated against by non-smokers. Restriction to designated smoking rooms (68%) or a ban on smoking (27%) would be supported by 95% of all employees. Even 89% of the smokers support smoking restrictions. These results show that there is a considerable demand for a smoke-free working environment among university hospital staff.